论文部分内容阅读
目的比较药物保守治疗和介入治疗稳定型心绞痛的效果。方法对136例稳定型心绞痛患者进行随访研究,按治疗方法不同分为药物治疗组(78例)和介入治疗组(58例),随访两组患者心脏事件发生率、再住院率、生存率、心功能情况及不良事件发生率。结果随访1年时药物组和介入组心脏事件发生率分别为7.7%和5.2%,再住院率分别为14.1%和6.9%,差异均无统计学意义(均P>0.05);随访3年时药物组和介入组心脏事件发生率分别为9.0%和6.9%,再住院率分别为15.4%和10.3%,生存率分别是98.7%和100%,差异也均无统计学意义(均P>0.05);经过治疗后介入组心功能改善和药物组相比差异无统计学意义(P>0.05),而介入组心绞痛复发率和再次血管重建术较药物组相比明显减少,差异均有统计学意义(P<0.05)。结论介入治疗和药物治疗对稳定型心绞痛患者的远期心脏事件发生率、减少再住院率、改善心功能、提高生存率都无明显差异。而介入治疗较药物治疗可明显降低稳定型心绞痛患者的心绞痛复发率、再次血管重建的发生率及不良事件总发生率。
Objective To compare the effects of conservative treatment and interventional treatment of stable angina pectoris. Methods A total of 136 patients with stable angina pectoris were followed up. According to the different treatment methods, the patients were divided into medication group (78 cases) and intervention group (58 cases). The incidences of cardiac events, readmission rate, survival rate, Cardiac function and incidence of adverse events. Results The incidence of cardiac events in the drug group and the intervention group at one year follow-up was 7.7% and 5.2%, respectively, and the rehospitalization rates were 14.1% and 6.9% respectively, with no significant difference (all P> 0.05) The incidence of cardiac events in the drug group and the intervention group were 9.0% and 6.9% respectively, and the rehospitalization rates were 15.4% and 10.3% respectively. The survival rates were 98.7% and 100% respectively, with no significant difference (all P> 0.05 ). After treatment, there was no significant difference in improvement of cardiac function between the intervention group and the drug group (P> 0.05). The recurrence rate of angina pectoris and revascularization in the intervention group were significantly decreased compared with the drug group, with statistical differences Significance (P <0.05). Conclusion Interventional therapy and drug therapy have no significant difference in the incidence of long-term cardiac events, rehospitalization rate, cardiac function and survival rate in patients with stable angina pectoris. Interventional therapy can significantly reduce the recurrence rate of angina pectoris, the incidence of revascularization and the overall incidence of adverse events in patients with stable angina pectoris compared with the drug treatment.